Camelid ISVDs for CD38 Targeting and Tissue Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current monoclonal antibodies for treating diseases with increased CD38 expression, such as cancer and autoimmune disorders, face challenges including instability, high production costs, limited tissue penetration, and reduced specificity and affinity due to their size and composition.
Innovation Solution
Development of immunoglobulin single variable domains (ISVDs) that specifically bind to CD38, with combinations of ISVDs targeting non-overlapping epitopes demonstrating synergistic effects and improved therapeutic efficacy, including biparatopic constructs linked to an Fc portion for enhanced complement-dependent cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to treat diseases with increased CD38 expression, then therapeutic efficacy is achieved, but production costs increase and stability decreases
Solution Approach 1:
The patent segments the conventional monoclonal antibody structure into smaller functional units, specifically using single variable domains (VHH) from camelid heavy chain antibodies. These VHH domains can be produced independently as stable, cost-effective building blocks that retain antigen-binding capability without requiring complex full antibody assembly processes
Solution Approach 2:
The patent changes the structural parameters of the antibody by adopting the VHH domain architecture from camelids, which naturally lacks the fragile regions found in conventional antibodies. This parameter change results in improved stability and reduced production costs while maintaining therapeutic efficacy
2Ease of operation
If conventional monoclonal antibodies are used, then antigen binding is achieved, but tissue penetration is limited due to size
Solution Approach 1:
The patent divides the large conventional antibody into smaller VHH domain segments, each capable of independent antigen binding. This segmentation reduces the overall size and complexity of the therapeutic agent, enabling better tissue penetration while preserving the essential antigen-binding function
Solution Approach 2:
The patent extracts only the essential antigen-binding variable domain (VHH) from the complete antibody structure, discarding the larger constant regions and other components. This extraction creates a minimized molecule with superior tissue penetration capabilities that retains the core therapeutic function
3Measurement precision
If polyclonal or monoclonal antibodies are used, then CD38 binding is achieved, but specificity and affinity are reduced
Solution Approach 1:
The patent optimizes the local quality of the antigen-binding site by focusing all design efforts on the VHH domain's complementarity determining regions (CDRs). This localized optimization enhances binding specificity and affinity without requiring complex modifications to the entire antibody molecule
Solution Approach 2:
The patent changes the structural parameters of the antigen-binding interface by utilizing the unique CDR architecture of camelid VHH domains, which can achieve higher affinity and specificity through extended CDR3 regions and different binding geometries compared to conventional antibodies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ISVDs exhibit potent binding to CD38-expressing tumor cells, outperforming individual ISVDs and benchmark antibodies in therapeutic efficacy, with enhanced tissue penetration and stability, and improved complement-dependent cytotoxicity.
Implementation Method 1
Antigen-binding polypeptides directed against CD38... which specifically bind to CD38
Implementation Method 2
biparatopic constructs linked to an Fc portion for enhanced complement-dependent cytotoxicity
Data Source
AI summary
Methods of targeting a CD38-expressing cell for treatment of at least one disease, disorder or condition that is associated with CD38. Polypeptides specifically binding to CD38 which are therefore suitable for the diagnosis and for the therapeutic and prophylactic treatment of diseases which are characterized by increased CD38 expression. Conjugates and pharmaceutical compositions comprising the polypeptides are disclosed as well. Use of such polypeptides in methods for the detection of CD38 and/or CD38-expressing cells in a biological sample. A process for the purification and concentration of CD38 and/or CD38-expressing cells in which the antigen-binding polypeptides are used are also described.